483
Gland Pharma Limited, Units I+II Pashamylaram SiteFDA 483 - Gland Pharma Limited, Units I+II Pashamylaram Site - August 26, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
Gland Pharma Limited in Hyderabad, India, a device manufacturer, was inspected by the FDA from August 23-26, 2023. The inspection revealed two significant issues: inadequate qualification of manufacturing equipment for Liraglutide Injection devices and failures in maintaining quality system records. These observations indicate deficiencies in both equipment validation and data management practices, including improper computer access.
- Inspection Date
- August 26, 2023
- Product Type
- Device
Open in Dashboard
ID · c2f4d2bb-1f08-4cc0-b659-19378e201a83